Oruka Therapeutics (NASDAQ:ORKA) Stock: Insider Arjun Agarwal Sells 9,999 Shares

Oruka Therapeutics, Inc. (NASDAQ:ORKA) SVP Arjun Agarwal sold 9,999 shares of Oruka Therapeutics stock in a transaction on Monday, October 12th. The shares were sold at an average price of $80.60, for a total value of $805,919.40. Following the transaction, the senior vice president owned 14,219 shares of the company’s stock, valued at $1,146,051.40. The trade was a 41.29% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Arjun Agarwal also recently made the following trade(s):

• On Monday, September 21st, Arjun Agarwal sold 533 shares of Oruka Therapeutics stock. The stock was sold at an average price of $95.75, for a total value of $51,034.75.
• On Tuesday, September 15th, Arjun Agarwal sold 560 shares of Oruka Therapeutics stock. The stock was sold at an average price of $95.71, for a total value of $53,597.60.
• On Friday, September 11th, Arjun Agarwal sold 9,459 shares of Oruka Therapeutics stock. The shares were sold at an average price of $92.23, for a total value of $872,403.57.
• On Thursday, August 13th, Arjun Agarwal sold 10,000 shares of Oruka Therapeutics stock. The shares were sold at an average price of $106.66, for a total value of $1,066,600.00.

Oruka Therapeutics Price Performance

ORKA opened at $76.68 on Thursday. The stock has a 50-day moving average price of $93.48 and a 200-day moving average price of $79.88. The firm has a market cap of $5.08 billion, a PE ratio of -37.77 and a beta of -0.37. Oruka Therapeutics, Inc. has a 1 year low of $25.11 and a 1 year high of $115.51.

Oruka Therapeutics (NASDAQ:ORKA) last announced its quarterly earnings results on Monday, August 10th. The company reported ($0.55) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.51) by ($0.04). As a group, sell-side analysts anticipate that Oruka Therapeutics, Inc. will post -2.42 EPS for the current year.

Analyst Upgrades and Downgrades

Several equities research analysts recently weighed in on ORKA shares. Weiss Ratings reissued a “sell (d-)” rating on shares of Oruka Therapeutics in a research report on Tuesday. HC Wainwright reissued a “buy” rating and issued a $120.00 target price on shares of Oruka Therapeutics in a research report on Thursday, September 24th. Guggenheim reiterated a “buy” rating and set a $200.00 target price on shares of Oruka Therapeutics in a research note on Tuesday, August 11th. Wedbush set a $120.00 price target on Oruka Therapeutics in a research note on Thursday, September 24th. Finally, Piper Sandler reiterated an “overweight” rating on shares of Oruka Therapeutics in a research note on Wednesday, October 7th. Ten analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, Oruka Therapeutics presently has a consensus rating of “Moderate Buy” and an average price target of $128.91.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently modified their holdings of the business. GAMMA Investing LLC lifted its position in shares of Oruka Therapeutics by 201.6% during the 3rd quarter. GAMMA Investing LLC now owns 374 shares of the company’s stock valued at $31,000 after buying an additional 250 shares in the last quarter. Engineers Gate Manager LP bought a new position in shares of Oruka Therapeutics during the 2nd quarter valued at approximately $350,000. Arizona State Retirement System grew its stake in shares of Oruka Therapeutics by 45.0% during the 2nd quarter. Arizona State Retirement System now owns 8,671 shares of the company’s stock valued at $825,000 after acquiring an additional 2,691 shares during the period. Nykredit A S purchased a new stake in Oruka Therapeutics in the 2nd quarter worth approximately $29,000. Finally, Braidwell LP purchased a new stake in Oruka Therapeutics in the 2nd quarter worth approximately $26,473,000. Hedge funds and other institutional investors own 56.44% of the company’s stock.

Oruka Therapeutics Company Profile

Oruka Therapeutics, Inc (NASDAQ: ORKA) is a clinical-stage biopharmaceutical company developing long-acting antibody therapies for immune-mediated diseases. The company’s approach is designed to extend the duration of treatment and potentially reduce the frequency of dosing for patients with chronic inflammatory conditions.

Oruka’s pipeline includes ORKA-001 and ORKA-002, next-generation monoclonal antibodies targeting interleukin-23 (IL-23), a cytokine involved in several autoimmune and inflammatory diseases.